News About: Pharm. Affairs
Targeted therapy developed by Hanmi, ‘Olita Tab’ approved as 27th domestic new drug
A Hanmi-developed targeted therapy for lung cancer acquired approval as the 27th domestic new drug.
The Ministry of Food and Drug Safety announced approval of the first domestically-developed targeted therapy for lun...
Celltrion’s Remsima announces dismissal of issuing ban suit of additional indication
Celltrion has started to enlarge its share in the Canadian market. On the 13th, Celltrion announced dismissal of the suit filed by Janssen to the Canadian court last September in regards to issuing ban of addition ind...
Olmesartan in crisis? Removal of discussion event schedule
The destiny of olmesartan – whose safety letter is distributed in Korea as removed from the insurance benefit by the French Agency for the Safety of Health Products(ANSM) due to suspicion in safety and validity – is e...
Domestic companies challenging Vesicare’s substance patent
On the 9th, Astellas Korea announced it filed a patent infringement prohibition suit over Vesicare jointly with its headquarters against CorePharm Bio to the Seoul Central District Court
Since no foreign pharmaceuti...
Most well-known erectile dysfunction therapy, ‘Viagra’ drops endlessly
The most well-known erectile dysfunction treatment, ‘Viagra’ has endlessly been fallen down.
Pfizer’s ‘Viagra’ which led the erectile dysfunction treatment market has rapidly been shrinking due to the aggressive offe...
10th RSA drug, Stivarga’ applied for health insurance on GIST patients
Stivarga Tab 40mg(regorafenib), a Bayer’s gastrointestinal stromal tumor(GIST) therapy, is going to be registered for the health insurance benefit from the 1st next month.
It will become the 10th drug with the risk-s...
‘Guzzling OTC Drug Price Research’ in final phase, to be announced by May
The research of guzzling OTC drugs’ selling prices entered the finalizing phase, expected to be announced by May as expected.
The Ministry of Health and Welfare announced the fact-finding research on guzzling OTC dr...
Boycott led by pharmacies against Oxy Reckitt Benckiser products spread across the nation
The boycott led by pharmacies against Oxy Reckitt Benckiser products has spread across the nation.
Caused by the Oxy Reckitt Benckiser’s irresponsible responses to the humidifier disinfectant death case, the boycott...
SC-type Remsima starts to aim for TNF-α inhibitor market
Celltrion started to conduct a clinical trial of the SC-type of Remsima, an autoimmune treatment, expanding its product competitiveness in the TNF-α inhibitor market. The company announced acquisition of the Phase 1 c...
Astellas’s ‘Vesicare’ filed lawsuit for infringement by CorePharm Bio
On the 4th, Astellas Korea(CEO Hae-do Jung) announced it jointly filed a patent infringement prohibition trial against CorePharm Bio with Astellas Korea to the Seoul Central District Court.
The trial is in regards t...
